What is HC Wainwright’s Estimate for EPRX Q1 Earnings?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for shares of Eupraxia Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 17th. HC Wainwright analyst B. Folkes anticipates that the company will earn ($0.23) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q3 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($1.05) EPS and FY2029 earnings at ($0.42) EPS.

Other equities research analysts also recently issued reports about the company. Wall Street Zen downgraded Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, January 22nd. Cantor Fitzgerald raised their price objective on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, January 15th. Zacks Research lowered Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday. Finally, Lifesci Capital upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ:EPRX opened at $7.60 on Thursday. The firm’s 50-day moving average is $8.28 and its 200-day moving average is $6.88. The company has a market cap of $273.30 million, a price-to-earnings ratio of -7.38 and a beta of 1.27. Eupraxia Pharmaceuticals has a 52-week low of $2.68 and a 52-week high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21).

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in EPRX. Ally Bridge Group NY LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at approximately $5,398,000. SummitTX Capital L.P. bought a new position in shares of Eupraxia Pharmaceuticals during the 4th quarter worth approximately $1,328,000. Royal Bank of Canada lifted its position in shares of Eupraxia Pharmaceuticals by 21.1% during the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after buying an additional 59,683 shares during the period. Ingalls & Snyder LLC boosted its stake in Eupraxia Pharmaceuticals by 31.0% in the 4th quarter. Ingalls & Snyder LLC now owns 77,400 shares of the company’s stock valued at $584,000 after buying an additional 18,300 shares in the last quarter. Finally, Cibc World Market Inc. grew its position in Eupraxia Pharmaceuticals by 287.0% in the fourth quarter. Cibc World Market Inc. now owns 58,050 shares of the company’s stock valued at $437,000 after acquiring an additional 43,050 shares during the period.

Eupraxia Pharmaceuticals News Roundup

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and an $11.00 price target on EPRX — this provides a clear bullish endorsement that can support the share price. Read More.
• Positive Sentiment: Lifesci Capital maintained a “Strong-Buy” stance on the stock, signaling continued institutional conviction despite model changes. Read More.
• Neutral Sentiment: HC Wainwright published detailed quarterly and multi‑year EPS projections (Q1–Q4 2026 and out-year forecasts through FY2030), giving investors updated guidance to model future cash needs and valuation — useful but not immediately directional. Read More.
• Negative Sentiment: Zacks Research downgraded EPRX from “Hold” to “Strong Sell,” which can pressure sentiment and trigger selling by model-driven funds or cautious retail investors. Read More.
• Negative Sentiment: HC Wainwright significantly cut EPS forecasts across multiple years (notably FY2026–FY2029 and FY2028), worsening near‑term profitability expectations and raising concerns about cash burn or longer timelines to commercialization. That reduction in earnings outlook is a substantive negative for valuation. Read More.
• Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS estimate (from -$0.75 to -$0.88) — a deterioration in near-term forecasts that may offset some of the positive signal from its “Strong-Buy” rating. Read More.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.